PH12021550017A1 - Ivosidenib forms and pharmaceutical compositions - Google Patents

Ivosidenib forms and pharmaceutical compositions

Info

Publication number
PH12021550017A1
PH12021550017A1 PH12021550017A PH12021550017A PH12021550017A1 PH 12021550017 A1 PH12021550017 A1 PH 12021550017A1 PH 12021550017 A PH12021550017 A PH 12021550017A PH 12021550017 A PH12021550017 A PH 12021550017A PH 12021550017 A1 PH12021550017 A1 PH 12021550017A1
Authority
PH
Philippines
Prior art keywords
ivosidenib
forms
pharmaceutical compositions
formulations
further provided
Prior art date
Application number
PH12021550017A
Other languages
English (en)
Inventor
Chong-Hui Gu
Jacob Paul Sizemore
Shijie Zhang
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of PH12021550017A1 publication Critical patent/PH12021550017A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PH12021550017A 2018-07-06 2021-01-04 Ivosidenib forms and pharmaceutical compositions PH12021550017A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862694596P 2018-07-06 2018-07-06
PCT/US2019/040257 WO2020010058A1 (en) 2018-07-06 2019-07-02 Ivosidenib forms and pharmaceutical compositions

Publications (1)

Publication Number Publication Date
PH12021550017A1 true PH12021550017A1 (en) 2021-09-13

Family

ID=69059942

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12021550017A PH12021550017A1 (en) 2018-07-06 2021-01-04 Ivosidenib forms and pharmaceutical compositions

Country Status (18)

Country Link
US (1) US12264148B2 (cg-RX-API-DMAC7.html)
EP (2) EP4603147A3 (cg-RX-API-DMAC7.html)
JP (2) JP7621242B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250164882A (cg-RX-API-DMAC7.html)
CN (1) CN112367995A (cg-RX-API-DMAC7.html)
AU (2) AU2019299352B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021000156A2 (cg-RX-API-DMAC7.html)
CA (1) CA3103498A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190217A1 (cg-RX-API-DMAC7.html)
IL (3) IL327008A (cg-RX-API-DMAC7.html)
MA (1) MA53099A (cg-RX-API-DMAC7.html)
MX (2) MX2021000068A (cg-RX-API-DMAC7.html)
PH (1) PH12021550017A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202012763TA (cg-RX-API-DMAC7.html)
TW (2) TWI911130B (cg-RX-API-DMAC7.html)
UA (1) UA129800C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020010058A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202008034B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT4010331T (pt) * 2019-08-08 2024-01-08 Servier Lab Um método de preparação do ivosidenib e de um seu intermediário
GB201912411D0 (en) * 2019-08-29 2019-10-16 Johnson Matthey Plc Crystalline forms of ivosidenib
AR133410A1 (es) 2023-08-01 2025-09-24 Servier Lab Cocristal de un inhibidor de idh1, proceso de preparación del mismo, composiciones farmacéuticas del mismo, y métodos de tratamiento que implican el mismo

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102985557B (zh) 2009-03-13 2018-06-15 安吉奥斯医药品有限公司 用于细胞增殖相关病症的方法和组合物
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
CN103459394B (zh) * 2011-04-08 2016-04-27 辉瑞大药厂 结晶和非结晶形式的托法替尼,以及包含托法替尼和渗透增强剂的药物组合物
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
JO3479B1 (ar) * 2012-09-06 2020-07-05 Bayer Healthcare Llc تركيبة دوائية مغلفة تحتوي على ريجورافنيب
PH12021551647A1 (en) * 2014-03-14 2022-06-06 Agios Pharmaceuticals Inc Pharmaceutical compositions of therapeutically active compounds
SMT202100444T1 (it) * 2014-03-14 2021-09-14 Les Laboratories Servier Sas Composizioni farmaceutiche di composti terapeuticamente attivi
MD3362066T2 (ro) * 2015-10-15 2022-08-31 Les Laboratoires Servier Sas Terapie combinată pentru tratamentul tumorilor maligne
CA3015753A1 (en) 2016-02-26 2017-08-31 Celgene Corporation Idh2 inhibitors for the treatment of haematological maligancies and solid tumours
EP3717470A1 (en) * 2017-11-27 2020-10-07 Assia Chemical Industries Ltd Solid state forms of ivosidenib

Also Published As

Publication number Publication date
MX2021000068A (es) 2021-03-25
TWI911130B (zh) 2026-01-01
TW202019419A (zh) 2020-06-01
IL315423B2 (en) 2026-08-01
TW202543623A (zh) 2025-11-16
JP2021529805A (ja) 2021-11-04
KR102919157B1 (ko) 2026-01-27
CN112367995A (zh) 2021-02-12
EA202190217A1 (ru) 2021-04-16
EP3817744A4 (en) 2022-07-13
IL315423B1 (en) 2026-04-01
CA3103498A1 (en) 2020-01-09
JP7621242B2 (ja) 2025-01-24
TWI902665B (zh) 2025-11-01
MA53099A (fr) 2021-05-12
AU2019299352B2 (en) 2025-02-27
UA129800C2 (uk) 2025-08-06
AU2025203835A1 (en) 2025-06-12
US20210323944A1 (en) 2021-10-21
IL327008A (en) 2026-05-01
IL279877A (en) 2021-03-01
EP4603147A3 (en) 2025-10-01
BR112021000156A2 (pt) 2021-04-06
KR20210029775A (ko) 2021-03-16
MX2023011687A (es) 2023-10-19
KR20250164882A (ko) 2025-11-25
JP2024150784A (ja) 2024-10-23
EP3817744A1 (en) 2021-05-12
AU2019299352A1 (en) 2021-01-07
WO2020010058A1 (en) 2020-01-09
US12264148B2 (en) 2025-04-01
SG11202012763TA (en) 2021-02-25
IL315423A (en) 2024-11-01
ZA202008034B (en) 2021-10-27
EP4603147A2 (en) 2025-08-20

Similar Documents

Publication Publication Date Title
MX2023011657A (es) Composiciones que comprenden curones y usos de los mismos.
MX2021002978A (es) Lactamas biciclicas y metodos de uso de las mismas.
PH12018500591A1 (en) Heterocyclic compounds and uses thereof
PH12020552154A1 (en) Compounds
MY210123A (en) Tlr7/8 antagonists and uses thereof
EP4279071A3 (en) Novel cannabinoid formulations
MX2021002529A (es) Analogos de illudin, usos de los mismos y metodos para sintetizar los mismos.
PH12020500105A1 (en) Bicyclic ketone compounds and methods of use thereof
MX2023011687A (es) Formas y composiciones farmaceuticas de ivosidenib.
CR20170591A (es) Benzamidas sustituidas y métodos para utilizarlas
JOP20200155A1 (ar) صور متعددة الأشكال
WO2018183631A8 (en) Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same
PH12018500378A1 (en) Novel annelated phenoxyacetamides
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
IL283286A (en) Pharmaceutical formulations of cyclosporine analogs
WO2020009675A3 (en) Solid oral pharmaceutical compositions of linagliptin
MX2019015869A (es) Nuevas formulaciones orales de belinostat.
IL283593A (en) Bernaflam oral preparations
IN2014MU00859A (cg-RX-API-DMAC7.html)
JOP20200025A1 (ar) مركبات جديدة تنشط مسار Nrf2
MX2016013428A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
MX2021002923A (es) (r)-5-carbamoilpiridin-3-il-2-metil-4-(3-(trifluorometoxi)bencil) piperazin-1-carboxilato cristalino, composiciones y sus metodos de uso.
MX2018010652A (es) Composiciones farmaceuticas.
MX2017010992A (es) Composiciones farmaceuticas estables que comprenden agente antibacteriano.
GB202005742D0 (en) Novel pharmaceutical compositions